AI assistant
H. Lundbeck A — Director's Dealing 2012
Aug 29, 2012
Preview isn't available for this file type.
Download source fileH. Lundbeck A/S hereby reports transactions made by executives and persons and
legal entities closely associated to them with shares in H. Lundbeck A/S and
linked securities, cf. section 28a of the Danish Securities Trading Act.
The list is based on reports received by H. Lundbeck A/S from the company's
executives today or yesterday.
Name: Ulf Wiinberg
Job position of the executive: President and CEO
ID code (ISIN code): DK 0010287234
Description of the security: Share
Nature of the transaction: Purchase of shares
Date of trading: 28 August 2012
Market on which the trading was effected: Nasdaq OMX Copenhagen
Number of traded securities: 4,000 shares
Market price of securities traded: DKK 438,400
Persons or entities under an obligation to report are defined as members of the
Executive Management and the Supervisory Board of H. Lundbeck A/S and
persons/entities closely associated to them.
Closely associated persons/entities means inter alia:
-- spouse or cohabitant
-- children below the age of 18
-- legal entities in which the insider has a controlling influence
The content of this release will have no influence on the Lundbeck Group’s
financial expectations for 2012.
Lundbeck contacts
Investors: Media:
Palle Holm Olesen Mads Kronborg
Chief Specialist, Investor Relations Media Relations Manager
[email protected] [email protected]
+45 36 43 24 26 +45 36 43 28 51
Magnus Thorstholm Jensen Simon Mehl Augustesen
Investor Relations Officer International Media Specialist
[email protected] [email protected]
+45 36 43 38 16 +45 36 43 49 80
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from brain disorders. For this purpose, Lundbeck is engaged in the research,
development, production, marketing and sale of pharmaceuticals across the
world. The company’s products are targeted at disorders such as depression and
anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and
Parkinson’s diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today
Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the
world’s leading pharmaceutical companies working with brain disorders. In 2011,
the company's revenue was DKK 16.0 billion (approximately EUR 2.1 billion or
USD 3.0 billion). For more information, please visit www.lundbeck.com.